Compare ARRY & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARRY | TNDM |
|---|---|---|
| Founded | 1989 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 2020 | 2013 |
| Metric | ARRY | TNDM |
|---|---|---|
| Price | $7.01 | $22.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 19 |
| Target Price | $10.24 | ★ $27.05 |
| AVG Volume (30 Days) | ★ 6.7M | 2.5M |
| Earning Date | 06-02-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,141,000.00 | $1,014,736,000.00 |
| Revenue This Year | $16.03 | $8.01 |
| Revenue Next Year | $7.79 | $12.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.22 | 7.93 |
| 52 Week Low | $3.76 | $10.00 |
| 52 Week High | $12.23 | $29.65 |
| Indicator | ARRY | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 49.46 |
| Support Level | $6.47 | $19.04 |
| Resistance Level | $10.02 | $22.98 |
| Average True Range (ATR) | 0.63 | 1.83 |
| MACD | -0.28 | -0.35 |
| Stochastic Oscillator | 8.15 | 20.25 |
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.